Shares for Interest Debt Settlement

Core Points - Arch Biopartners Inc. has arranged a shares for debt transaction to settle $57,246.57 in interest on a deferred convertible note as of February 1, 2025 [1][2] - The transaction involves issuing 31,112 common shares at a deemed price of$1.84, pending approval from the TSX Venture Exchange [2][3] - The total notional value of the note is $500,000 CAD, which will convert into 561,798 common shares at maturity [3] Company Overview - Arch Biopartners Inc. is focused on preventing acute kidney injury and organ damage caused by inflammation, developing drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway [4] - The lead drug candidates include LSALT peptide and cilastatin, aimed at addressing significant unmet medical needs related to kidney injury [4] - The company has 64,940,956 common shares outstanding [5]